Amycretin Dosage, half-life & reference guide

Also known as Zenagamtide · NNC0487-0111 · Amy

Reviewed 6 studiesEvidence: ModeratePublished by PepVault

One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. In a small phase 1b/2a trial, weekly shots took off about 22% of body weight at 20 mg and 24% at 60 mg over 36 weeks; in type 2 diabetes, up to about 14.5% at 36 weeks.

Studied range
0.4–60 mgstarting dose 0.2 mg
How often
Weekly
Half-life
~88 hours
Evidence
●●● Moderate
Route
SubQ injection

Studied in research — not a recommendation.

Amycretin dose guide

How it works.

One peptide that switches on both the GLP-1 receptor and the amylin receptors (and the calcitonin receptor), so it carries the two signals CagriSema gives as two drugs. GLP-1 curbs appetite and slows the stomach; amylin adds fullness after meals. A fatty-acid side chain binds it to albumin in the blood, so a weekly shot lasts. Novo Nordisk is developing it as a weekly injection and as a daily tablet. Investigational, in phase 3 since February 2026.

Commonly reported: In trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere.

Half-life & active level

The half-life of Amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).

Here's how a typical Amycretin schedule accumulates over four weeks (one-compartment estimate).

An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.

A smiling woman in a dark training top in her kitchen, holding a glass of water

Model. Individual results vary.

PepVault for iPhone

Track amycretin in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Where Amycretin works.

A body with Appetite & metabolism lit
  • Appetite & metabolism

    In people. In a 36-week trial in type 2 diabetes, weekly amycretin lowered HbA1c by about 0.9 to 1.7 points depending on dose, and weight by up to about 14.5%.

An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.

Week by week.

What to expect in the first 8 weeks

Onset
Days–2 weeks
Peak effect
36 weeks (longest trial so far)
Duration
Ongoing
  1. Day 1–28RCT

    A very low start

    Amycretin's trials begin at a fraction of a milligram and step up every 4 weeks. Commonly reported: appetite dropping within days even on the first dose. The GI side effects in its trials came mostly with the step-ups.

    The science

    Phase 2 in type 2 diabetes started every arm at 0.2 mg with escalations every 4 weeks to 0.4-40 mg (Mora 2026, Lancet; NCT06542874); the phase 1b/2a obesity trial escalated from 0.3 mg (Dahl 2025, Lancet; NCT06064006). Most adverse events were GI and mild to moderate in both.

    Sources
    • Mora et al. (2026)
    • Dahl et al. (2025)

    Updated Nov 2026

  2. Any dayRCT

    What Amycretin is built on

    Two phase 1 trials and two phase 2 trials, all in the Lancet, plus a kidney study. Its phase 3 programs for weight (AMAZE) and diabetes (AMBITION) began in 2026. It is not approved anywhere.

    The science

    Rodent work: in obese rats, 21 days of amycretin cut food intake by 47% and body weight by 18% and reduced liver fat, and it reached the brain areas that govern food intake in mice (Kuhre 2025, EBioMedicine). First-in-human oral (Gasiorek 2025, Lancet; single centre, San Antonio). Phase 1b/2a SubQ (Dahl 2025, Lancet; 125 people). Phase 2 in type 2 diabetes, SubQ and oral (Mora 2026, Lancet; NCT06542874). Renal PK: half-life 88.1 h in normal kidney function (Oldenburg 2026, Diabetes Obes Metab; NCT06559527). Phase 3: AMAZE 1 (NCT07339423, 1,150 people, four SubQ dose levels, from Feb-2026) and more than ten other AMAZE and AMBITION trials, all sponsored by Novo Nordisk.

    Sources
    • Kuhre et al. (2025)
    • Gasiorek et al. (2025)
    • Dahl et al. (2025)
    • Mora et al. (2026)
    • Oldenburg et al. (2026)

    Updated Nov 2026

  3. With BPC-157Community

    Why people add BPC-157 to a GLP-1

    GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.

    The science

    BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside amycretin or any GLP-1 drug; the pairing comes from community reports.

    Sources
    • Sikiric et al. (2018)

    Updated Nov 2026

After week 8

  1. Day 57–140 · 1.25 mgClinical

    The lowest dose tested for weight

    You're at 1.25 mg, the smallest maintenance dose in the obesity trial. That group lost about 9.7% of body weight in 20 weeks, against a small gain on placebo.

    The science

    Phase 1b/2a Part E: escalated from 0.3 mg to 1.25 mg, 20 weeks in total with the last 12 at maintenance: −9.7% vs +2.0% on placebo at week 20 (p = 0.0003) (Dahl 2025). Single centre (San Antonio), small groups, and many withdrawals for reasons other than side effects, so the estimates are early.

    Sources
    • Dahl et al. (2025)

    Updated Nov 2026

  2. Day 85–252RCT

    With type 2 diabetes

    In a 36-week trial in type 2 diabetes, weekly amycretin lowered HbA1c by about 0.9 to 1.7 points depending on dose, and weight by up to about 14.5%. Up to about 9 in 10 people on it reached an HbA1c under 7%.

    The science

    Phase 2 SubQ (Mora 2026, Lancet; 262 adults on metformin with or without an SGLT2 inhibitor, 83 sites in 11 countries; doses 0.4 to 40 mg): HbA1c −0.9% (0.4 mg) to −1.7% (40 mg) from 7.8%; serious adverse events in 8% across all groups, no deaths. Novo reported weight loss up to 14.5% and up to 89.1% reaching HbA1c below 7% (Novo Nordisk, Feb-3-2026). The daily tablet in the same program lowered HbA1c by 0.9 to 1.4 points at 6 to 50 mg (Mora 2026, oral).

    Sources
    • Mora et al. (2026)
    • Novo Nordisk (FY2025 report) (2026)

    Updated Nov 2026

  3. Day 113–196 · 5 mgClinical

    Five milligrams

    You're at 5 mg. In the obesity trial, the 5 mg group averaged about 16% weight loss at 28 weeks. Commonly reported: smaller portions and fewer cravings, with a few queasy days after each step.

    The science

    Phase 1b/2a Part D: escalated from 0.3 mg to 5 mg, 28 weeks in total with the last 12 at maintenance: −16.2% vs +2.3% on placebo at week 28 (p < 0.0001) (Dahl 2025).

    Sources
    • Dahl et al. (2025)

    Updated Nov 2026

  4. Day 169–252 · 20 mgClinical

    Twenty milligrams

    You're at 20 mg. In the obesity trial, the 20 mg group averaged about 22% weight loss at 36 weeks, and a 60 mg group reached about 24%.

    The science

    Phase 1b/2a Part C: escalated from 0.3 mg to 20 mg, 36 weeks: −22.0% vs +1.9% on placebo; Part B: escalated to 60 mg, −24.3% vs −1.1% at week 36 (both p < 0.0001) (Dahl 2025). The authors called the GI event rate high but in line with early studies of GLP-1 and amylin agonists.

    Sources
    • Dahl et al. (2025)

    Updated Nov 2026

  5. Day 253+Clinical

    A long-term medicine, not a course

    Worth knowing before you stop: with GLP-1 drugs, coming off usually means regaining most of the loss within about a year and a half. Amycretin hasn't been tested in a stopping trial, so this is the pattern of other weight drugs. Continue, taper or stop is a call for you and your clinician.

    The science

    A BMJ meta-analysis found that after stopping semaglutide or tirzepatide, about 9.9 kg came back within the first year, with weight projected back to baseline about 1.5 years after stopping (West 2026). No withdrawal trial of amycretin has been published; Novo's phase 3 program includes a weight-maintenance trial (AMAZE 12).

    Sources
    • West et al. (2026)

    Updated Nov 2026

Day 1 is the day you start it.

Phase 1 and 1b/2a (Dahl 2025, Lancet; Gasiorek 2025, Lancet), phase 2 in type 2 diabetes (Mora 2026, Lancet, SubQ and oral), renal PK (Oldenburg 2026), Novo Nordisk report Feb-3-2026, AMAZE and AMBITION records on ClinicalTrials.gov. Investigational.

Moderate evidence

Mixing and a typical run.

Example numbers

Reconstitution example

Reconstitute a 10 mg vial of Amycretin with 3 mL of bacteriostatic water and a 0.2 mg dose is 6 units on a U-100 syringe, about 50 doses per vial.

Vial
10 mg
Water
3 mL
Amount
0.2 mg

Draw to6 units

0.3 mL insulin syringe · 30 units

Mix it in the Reconstitution LabOpen the calculator

Run notes

Cycle
Used continuously, once weekly, in its trials: up to 36 weeks so far, with doses stepped up every 4 weeks. No trial has tested stopping it.Community practice — opinions vary. Not a clinical recommendation.
Timing
Once weekly SubQ, same day each week, in its trials, stepped up every 4 weeks: from 0.2 mg in the diabetes trial and 0.3 mg in the obesity trial. Maintenance doses ran from 0.4 to 60 mg. The tablet is a daily dose in its own trials (6 to 50 mg in phase 2), not interchangeable mg for mg with the shot. These are trial schedules, not an approved regimen.
Route
SubQ injection
Stacks
BPC-157 (GI support)

Track it in the app

Safety.

Common side effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Decreased appetite

Interactions

No interaction studies have been published. GLP-1 and amylin both slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself (and already carries an amylin signal), so it is not stacked with another GLP-1 or with cagrilintide. In a kidney study, exposure was 13% to 35% higher with reduced kidney function, which the authors judged not to need a dose change. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.

Safety notes

Amycretin has no label: it is still in trials. In the phase 1b/2a obesity trial, the most common side effects were GI, mostly mild to moderate and gone by the end of the study; the authors called the GI rates high but similar to early studies of other GLP-1 and amylin drugs. In the 36-week phase 2 trial in type 2 diabetes, most side effects were GI and mild to moderate, and serious events were spread across doses and placebo (8% overall, no deaths). It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.

Mixing charts by vial size.

Questions people ask.

What is Amycretin?

One peptide from Novo Nordisk that gives both the GLP-1 and the amylin signal, the pair CagriSema delivers as two drugs, as a weekly shot or a daily tablet. In a small phase 1b/2a trial, weekly shots took off about 22% of body weight at 20 mg and 24% at 60 mg over 36 weeks; in type 2 diabetes, up to about 14.5% at 36 weeks.

How is Amycretin dosed in research?

The research range for Amycretin is 0.4–60 mg, weekly, with a 0.2 mg starting dose. Studied in research — not a recommendation.

How long does Amycretin last?

The half-life of Amycretin is ~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026).

What do people report on Amycretin?

Commonly reported on Amycretin: in trials, strong appetite loss and GI side effects during the step-ups. Now named zenagamtide; in phase 3 and not approved anywhere.

Is Amycretin safe?

The research basis for Amycretin is moderate: animal studies + some human data. Common side effects in the library: nausea, vomiting, diarrhea and decreased appetite.

What does Amycretin stack with?

Common stacks for Amycretin: BPC-157 (GI support).

Track it in the app

Research.

The literature

Search the latest research

Reference.

Cadence

Weekly

Half-life

~88 hours

~88 hours (measured in people: 88.1 h after a single 0.3 mg SubQ dose with normal kidney function; Oldenburg 2026)

Research basis

●●● Moderate

Animal studies + some human data

PepVault for iPhone

Track amycretin in PepVault

Log each dose, see how many doses are left in the vial, and keep your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo

Reviewed How we check the library